Prognostic value of hemoglobin-to-red cell distribution width ratio and inflammation markers in colorectal cancer

Table 1 Clinicopathological features of the patients

Patients’ characteristics	Number	%
Age
< 65	94	60.6
≥ 65	61	39.4
Sex
Male	99	63.9
Female	56	36.1
ECOG PS
< 2	55	64.5
≥ 2	100	35.5
Tumor location
Right	31	20.0
Left	124	80.0
Tumor grade
< 2	22	14.2
≥ 2	133	85.8
Body mass index
< 25	68	43.9
≥ 25	87	56.1
Metastasis status
De novo	96	61.9
Recurrence	59	38.1
Liver metastasis
No	47	30.3
Yes	108	69.7
Lung metastasis
No	93	60.0
Yes	62	40.0
Peritoneal metastasis
No	119	76.8
Yes	36	23.2
Metastasectomy
No	123	79.4
Yes	32	20.6
Treatment lines
< 3	112	72.3
≥ 3	43	27.7
Laboratory parameters	Low1	High1
CEA (ng/dL)	71 (45.8)	84 (54.2)
CA19-9 (U/mL)	78 (50.3)	77 (49.7)
NLR	78 (50.3)	77 (49.7)
PLR	78 (50.3)	77 (49.7)
SII	78 (50.3)	77 (49.7)
MLR	77 (49.7)	78 (50.3)
HRR	77 (49.7)	78 (50.3)
PRR	81 (52.3)	74 (47.7)
PDWLR	75 (48.4)	80 (51.6)

¹Low and high values were calculated according to optimal cutoffs.

Data are presented as n (%). ECOG PS: Eastern Cooperative Oncology Group-performance score; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index; MLR: Monocyte-to-lymphocyte ratio; HRR: Hemoglobin-to-red cell distribution width ratio; PRR: Platelet-to-red cell distribution width ratio; PDWLR: Platelet distribution width to lymphocyte ratio.

Table 2 Cox regression analysis for overall survival values

Variable	Category	Univariate analysis		Multivariate analysis
		HR (95%CI)	P value	HR (95%CI)	P value
Patients’ characteristics
Sex	Male/female	0.66 (0.44-0.99)	0.0451
ECOG PS	< 2/≥ 2	1.25 (0.84-1.87)	0.270
Body mass index	< 25/≥ 25	1.42 (0.95-2.13)	0.084
Age	< 65/≥ 65	1.51 (1.02-2.25)	0.0401	1.59 (1.06-2.39)	0.0251
Tumor grade	< 2/≥ 2	0.97 (0.56-1.65)	0.897
Tumor location	Right/left	1.51 (0.87-2.63)	0.142
Metastasis status	De novo/recurrence	1.09 (0.72-1.66)	0.693
Liver metastasis	No/yes	0.99 (0.64-1.54)	0.976
Peritoneal metastasis	No/yes	1.32 (0.81-2.15)	0.273
Lung metastasis	No/yes	0.90 (0.60-1.35)	0.607
Metastasectomy	No/yes	0.42 (0.24-0.71)	0.0011	0.49 (0.29-0.85)	0.0111
Treatment lines	< 3/≥ 3	0.86 (0.70-1.07)	0.168
Laboratory parameters
CEA (ng/dL)	< 6.1/≥ 6.1	1.70 (1.14-2.55)	0.0101	1.51 (1.00-2.28)	0.0481
CA19-9 (U/mL)	< 21.6/≥ 21.6	1.34 (0.91-1.98)	0.138
NLR	< 3.09/≥ 3.09	1.38 (0.93-2.04)	0.108
PLR	< 177.5/≥ 177.5	1.57 (1.06-2.33)	0.0241	1.63 (1.09-2.44)	0.0181
SII	< 835.96/≥ 835.96	1.67 (1.13-2.46)	0.0101
MLR	< 0.38/≥ 0.38	1.00 (0.67-1.48)	0.988
HRR	< 0.83/≥ 0.83	0.64 (0.43-0.95)	0.0251
PRR	< 18.85/≥ 18.85	1.19 (0.80-1.77)	0.384
PDWLR	< 10.87/≥ 10.87	1.05 (0.71-1.57)	0.794

¹Significant values. ECOG PS: Eastern Cooperative Oncology Group-performance score; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index; MLR: Monocyte-to-lymphocyte ratio; HRR: Hemoglobin-to-red cell distribution width ratio; PRR: Platelet-to-red cell distribution width ratio; PDWLR: Platelet distribution width to lymphocyte ratio; HR: Hazard ratio; CI: Confidence interval.